# AnchorDx

Source: https://onco.cc/companies/anchordx/  
OnCo record `anchordx` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A Guangzhou company making DNA methylation tests in blood and urine, which announced a six-cancer blood test, Aurora, in 2020.

## Summary

AnchorDx Medical, of Guangzhou, with a US entity in Fremont, California, according to its authors' affiliations, has published methylation assays for lung, bladder, kidney and colorectal cancer and a two-cancer colorectal and gastric study. It announced Aurora, a methylation blood test for six cancers, in June 2020.

## Fields

- Kind: Company
- Last checked: 2026-11-03
- Also known as: AnchorDx Medical Co., Ltd.
- HQ: Guangzhou
- Type: diagnostics

## Sources

- Lei et al., American Journal of Cancer Research 2024: https://doi.org/10.62347/TPTQ3682

## Connected records

- fronts: [Diagnostics & Biomarkers](https://onco.cc/fronts/diagnostics/), [Early Detection & Screening](https://onco.cc/fronts/early-detection/)
- technologies: [Cell-free DNA methylation tests](https://onco.cc/technologies/cfdna-methylation-testing/), [Liquid biopsy (ctDNA)](https://onco.cc/technologies/liquid-biopsy/), [Multi-cancer early detection (MCED)](https://onco.cc/technologies/mced/)
- drugs: [Aurora (AnchorDx)](https://onco.cc/drugs/anchordx-aurora/)

---
JSON: https://onco.cc/api/v1/entities/anchordx.json